MD Anderson Research Highlights for August 11, 2021

Current advances include insights into anti-tumor responses, a targeted therapy combination for biliary tract cancers, biomarkers that may predict response to DNA damage repair inhibitors, a “virtual biopsy” using artificial intelligence to characterize tumors, new targeted and immunotherapy approaches for pancreatic cancer, understanding the impact of TP53 mutations on acute myeloid leukemia treatments, as well as a new strategy to overcome treatment-resistant KRAS-mutant lung cancer.

Study Identifies Never-Before-Seen Dual Function in Enzyme Critical for Cancer Growth

In developing therapies for hard-to-treat breast and ovarian cancers in patients with BRCA gene mutations, scientists aim to identify ways to keep cancer cells from using DNA break repair pathways. New findings demonstrate a previously-unknown capability for polymerase theta (pol theta) – a key enzyme in this repair function – that shows promise as a new avenue for treatment development.